1426298-01-2

Basic information

• Product Name: (S)-acetic acid 3-(3,4-diethoxyphenyl)-2-methanesulfonyloxymethylpropyl ester
• Synonyms: (S)-acetic acid 3-(3,4-diethoxyphenyl)-2-methanesulfonyloxymethylpropyl ester
• CAS NO: 1426298-01-2
• Molecular Weight: 374.455
• Mol File: 1426298-01-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-acetic acid 3-(3,4-diethoxyphenyl)-2-methanesulfonyloxymethylpropyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-acetic acid 3-(3,4-diethoxyphenyl)-2-methanesulfonyloxymethylpropyl ester(1426298-01-2)
• EPA Substance Registry System: (S)-acetic acid 3-(3,4-diethoxyphenyl)-2-methanesulfonyloxymethylpropyl ester(1426298-01-2)

Safety Data

• Hazardous Substances Data: 1426298-01-2(Hazardous Substances Data)

Upstream product

• 2029-94-9 3,4-diethoxybenzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 1426298-00-1 (R)-acetic acid 3-(3,4-diethoxyphenyl)-2-hydroxymethylpropyl ester 
• 124-63-0 methanesulfonyl chloride 
• 1426297-99-5 2-(3,4-diethoxybenzyl)malonic acid diethyl ester 
• 83459-29-4 (3,4-diethoxyphenyl)methanol 

Downstream Products

• 1426297-86-0 (3R,4R)-3-(4-benzyloxy-3-methoxybenzyl)-4-(3,4-diethoxybenzyl)dihydrofuran-2-one 
• 1426297-87-1 (3R,4R)-3-(4-benzyloxy-3-ethoxybenzyl)-4-(3,4-diethoxybenzyl)dihydrofuran-2-one 
• 1426297-95-1 C₂₃H₂₈O₆ 
• 1426297-96-2 C₂₄H₃₀O₆ 
• 1426297-78-0 (R)-4-(3,4-diethoxybenzyl)dihydrofuran-2-one 

Relevant articles and documents

Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy

A series of new (-)-arctigenin derivatives with variably modified O-alkyl groups were synthesized and their preferential cytotoxicity was evaluated against human pancreatic cancer cell line PANC-1 under nutrient-deprived conditions. The results showed that monoethoxy derivative 4i (PC50, 0.49 μM), diethoxy derivative 4h (PC50, 0.66 μM), and triethoxy derivative 4m (PC50, 0.78 μM) showed the preferential cytotoxicities under nutrient-deprived conditions, which were identical to or more potent than (-)-arctigenin (1) (PC50, 0.80 μM). Among them, we selected the triethoxy derivative 4m and examined its in vivo antitumor activity using a mouse xenograft model. Triethoxy derivative 4m exhibited also in vivo antitumor activity with the potency identical to or slightly more than (-)-arctigenin (1). These results would suggest that a modification of (-)-arctigenin structure could lead to a new drug based on the antiausterity strategy.